11/23/20 9:30 AMNYSE : BSXBoston Scientific to Participate in Evercore ISI 2020 Healthcare ConferenceBoston Scientific Corporation (NYSE: BSX) is scheduled to participate in the 2020 Evercore ISI HealthCONx Conference on December 1.Mike Mahoney, chairman and chief executive officer, and Susie Lisa, vice president, Investor Relations willRHEA-AIneutral
11/17/20 6:00 AMNYSE : BSXBoston Scientific Announces LOTUS Edge(TM) Aortic Valve System Voluntary Recall and Product DiscontinuationBoston Scientific Corporation (NYSE: BSX) has announced it has initiated a global, voluntary recall of all unused inventory of the LOTUS Edge (TM) Aortic Valve System due to complexities associated with the product delivery system. The voluntary recallRHEA-AIneutral
11/05/20 9:30 AMNYSE : BSXBoston Scientific Announces November 2020 Conference ScheduleBoston Scientific Corporation (NYSE: BSX) will participate in two upcoming virtual investor conferences.On November 12, 2020, Meghan Scanlon, senior vice president and president, Urology and Pelvic Health, and Susie Lisa, vice president, InvestorRHEA-AIneutral
11/02/20 9:41 AMNYSE : BSXBoston Scientific Receives FDA Approval for the Ranger(TM) Drug-Coated BalloonBoston Scientific (NYSE: BSX) announced it has received U.S. Food and Drug Administration (FDA) approval of the Ranger(TM) Drug-Coated Balloon, developed for the treatment of patients with peripheral artery disease (PAD) in the superficial femoralRHEA-AIpositive
10/29/20 6:55 AMNYSE : BSXBoston Scientific Initiates Trial to Evaluate WATCHMAN FLX(TM) Left Atrial Appendage Closure Device as First-Line Treatment for People at Risk of StrokeBoston Scientific Corporation (NYSE: BSX) has initiated the CHAMPION-AF clinical trial to evaluate the safety and efficacy of the WATCHMAN FLX(TM) Left Atrial Appendage Closure (LAAC) Device within a broad population of patients with non-valvularRHEA-AIneutral
10/28/20 6:30 AMNYSE : BSXBoston Scientific Announces Results For Third Quarter 2020Boston Scientific Corporation (NYSE: BSX) generated sales of $2.659 billion during the third quarter of 2020. This represents a decline of (1.8) percent on a reported basis, (2.5) percent on an operational 1 basis and (5.7) percent on an organic 2RHEA-AIneutral
10/01/20 9:30 AMNYSE : BSXBoston Scientific Announces Transcatheter Cardiovascular Therapeutics 2020 Investor Update and Conference Call Discussing Third Quarter 2020 ResultsBoston Scientific Corporation (NYSE: BSX) will webcast an investor update at the virtual 2020 Transcatheter Cardiovascular Therapeutics (TCT) on Thursday, October 15 from 1:00 - 2:00 p.m. EDT. Joe Fitzgerald, executive vice president and president,RHEA-AIneutral
09/30/20 4:01 PMNYSE : BSXBoston Scientific Launches WaveWriter Alpha(TM) Spinal Cord Stimulator Systems In EuropeBoston Scientific (NYSE: BSX) today announced the European launch of the WaveWriter Alpha(TM) portfolio of Spinal Cord Stimulator (SCS) Systems. The portfolio, consisting of four MRI conditional i, Bluetooth-enabled implantable pulse generatorsRHEA-AIpositive
09/28/20 6:45 AMNYSE : BSXBoston Scientific Launches ACURATE neo2(TM) Aortic Valve System in EuropeBoston Scientific Corporation (NYSE: BSX) today announced it has initiated a controlled launch of the ACURATE neo2 (TM) Aortic Valve System in Europe. This next-generation transcatheter aortic valve implantation (TAVI) technology is a new platformRHEA-AIneutral
09/21/20 7:00 AMNYSE : BSXBoston Scientific Announces Expanded Investment and Exclusive Acquisition Option Agreement with Farapulse, Inc.Boston Scientific Corporation (NYSE: BSX) today announced it has signed an investment agreement with an exclusive option to acquire Farapulse, Inc., a privately-held company developing a pulsed field ablation (PFA) system for the treatment ofRHEA-AIneutral
